Physician profile
Michelle E Tulla
NPI 1386841674
$545.88
in general payments reported to CMS, 2019-2025
13 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.79 · 2023: $117 · 2024: $230 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $115.61 | 2024 | |
| Abbvie INC. | $68.19 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $54.22 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $46.42 | 2023-2024 | Doc Band |
| Collegium Pharmaceutical, INC. | $43.72 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $43.62 | 2025 | Relexxii |
| Corium, LLC | $38.03 | 2023 | Azstarys |
| Organon LLC | $31.12 | 2022 | |
| Alk-Abello, INC | $26.89 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $26.29 | 2024 | Ycanth |
| Mayne Pharma Commercial LLC | $19.92 | 2025 | |
| Sanofi Pasteur INC. | $16.18 | 2024 | |
| Phadia US INC. | $15.67 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Tulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.